JP Morgan Maintains Overweight on Adaptive Biotechnologies, Lowers Price Target to $19

Benzinga Newsdesk www.benzinga.com Negative 83.6%

Neg 83.6% Neu 0% Pos 0%

JP Morgan analyst Sebastian Sandler maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and lowers the price target from $21 to $19.